We are live on
!
Find out more
RhumbLine Advisers Portfolio holdings
AUM
$117B
1-Year Est. Return
29.66%
This Fund
S&P 500
This Quarter
Est. Return
+6.08%
1 Year Est. Return
+29.66%
3 Year Est. Return
+101.47%
5 Year Est. Return
+137.35%
10 Year Est. Return
+530.91%
AUM
$42.8B
AUM Growth
+$3.35B
(+8.5%)
Cap. Flow
+$1.35B
Cap. Flow
% of AUM
3.15%
Top 10 Holdings %
Top 10 Hldgs %
14.82%
Holding
2,894
New
39
Increased
2,631
Reduced
168
Closed
44
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Abbott
ABT
|
+$21.8M |
| 2 |
Chevron
CVX
|
+$20.5M |
| 3 |
Berkshire Hathaway Class B
BRK.B
|
+$19.7M |
| 4 |
Incyte
INCY
|
+$17.8M |
| 5 |
ExxonMobil
XOM
|
+$16.9M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
SE
Spectra Energy Corp Wi
SE
|
+$49.6M |
| 2 |
STJ
St Jude Medical
STJ
|
+$41.1M |
| 3 |
LLTC
Linear Technology Corp
LLTC
|
+$30.3M |
| 4 |
HAR
Harman International Industries
HAR
|
+$13.8M |
| 5 |
ENH
Endurance Specialty Holdings Ltd
ENH
|
+$10.3M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Financials | 16.2% |
| 2 | Technology | 15.06% |
| 3 | Healthcare | 13.05% |
| 4 | Industrials | 10.88% |
| 5 | Consumer Discretionary | 9.27% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
FFIC
1801
DELISTED
Flushing Financial
FFIC
| $1.28M | ﹤0.01% |
47,714
+1,179
| +3% | +$32.9K |
|
1802
MarineMax
HZO
$759M
| $1.28M | ﹤0.01% |
59,216
+13,273
| +29% | +$279K |
|
|
PGNX
1803
DELISTED
Progenics Pharmaceuticals Inc
PGNX
| $1.28M | ﹤0.01% |
135,769
+58,042
| +75% | +$579K |
|
1804
TherapeuticsMD
TXMD
$23.5M
| $1.28M | ﹤0.01% |
3,544
+194
| +6% | +$60K |
|
|
ESND
1805
DELISTED
Essendant Inc.
ESND
| $1.27M | ﹤0.01% |
83,590
+23,092
| +38% | +$429K |
|
|
OCLR
1806
DELISTED
Oclaro Inc.
OCLR
| $1.26M | ﹤0.01% |
128,795
+5,029
| +4% | +$47.2K |
|
1807
OneMain Financial
OMF
$7.2B
| $1.26M | ﹤0.01% |
50,847
+1,788
| +4% | +$44.9K |
|
1808
M/I Homes
MHO
$3.74B
| $1.26M | ﹤0.01% |
51,507
+13,814
| +37% | +$339K |
|
|
SUP
1809
DELISTED
Superior Industries International
SUP
| $1.26M | ﹤0.01% |
49,611
+12,581
| +34% | +$309K |
|
|
PRFT
1810
DELISTED
Perficient Inc
PRFT
| $1.26M | ﹤0.01% |
72,459
+19,362
| +36% | +$345K |
|
1811
Precigen
PGEN
$2.24B
| $1.25M | ﹤0.01% |
63,051
+96
| +0.2% | +$2.14K |
|
|
INVN
1812
DELISTED
Invensense Inc
INVN
| $1.25M | ﹤0.01% |
98,784
+5,660
| +6% | +$70.5K |
|
1813
Puma Biotechnology
PBYI
$404M
| $1.25M | ﹤0.01% |
33,462
+1,429
| +4% | +$52.1K |
|
|
RUTH
1814
DELISTED
Ruth's Hospitality Group, Inc.
RUTH
| $1.24M | ﹤0.01% |
62,039
+16,426
| +36% | +$295K |
|
1815
Rayonier Advanced Materials
RYAM
$604M
| $1.24M | ﹤0.01% |
92,358
+29,854
| +48% | +$419K |
|
1816
John B. Sanfilippo & Son
JBSS
$967M
| $1.24M | ﹤0.01% |
16,903
+7,055
| +72% | +$465K |
|
|
WIN
1817
DELISTED
Windstream Holdings Inc
WIN
| $1.24M | ﹤0.01% |
45,308
+21,824
| +93% | +$780K |
|
1818
First Busey Corp
BUSE
$2.57B
| $1.23M | ﹤0.01% |
41,902
+1,352
| +3% | +$40.8K |
|
|
ANAT
1819
DELISTED
American National Group, Inc. Common Stock
ANAT
| $1.23M | ﹤0.01% |
10,432
+2,120
| +26% | +$253K |
|
|
UBA
1820
DELISTED
Urstadt Biddle Properties Inc. Class A
UBA
| $1.23M | ﹤0.01% |
59,739
+18,193
| +44% | +$401K |
|
|
FRGI
1821
DELISTED
Fiesta Restaurant Group, Inc.
FRGI
| $1.23M | ﹤0.01% |
50,611
+14,697
| +41% | +$372K |
|
|
FPRX
1822
DELISTED
Five Prime Therapeutics, Inc.
FPRX
| $1.22M | ﹤0.01% |
33,798
+970
| +3% | +$42.8K |
|
|
UBNK
1823
DELISTED
United Financial Bancorp, Inc.
UBNK
| $1.22M | ﹤0.01% |
71,599
+2,379
| +3% | +$41.8K |
|
|
HSKA
1824
DELISTED
Heska Corp
HSKA
| $1.21M | ﹤0.01% |
11,555
+4,867
| +73% | +$416K |
|
|
ONCE
1825
DELISTED
Spark Therapeutics, Inc. Common Stock
ONCE
| $1.21M | ﹤0.01% |
22,652
+883
| +4% | +$52.4K |
|
Similar funds
VAM
RhumbLine Advisers's Q1 2017 Portfolio in Review
As of Q1 2017, RhumbLine Advisers held 2,894 positions worth $42.8B, up 8.5% from $39.5B the previous quarter. Its ten largest holdings account for 15% of the portfolio.
RhumbLine Advisers deployed $1.35B of net new capital in Q1 2017, opening 39 new positions and adding to 2,631 existing holdings. Its largest new stake was Bioverativ Inc. Common Stock: 197,812 shares worth $10.8M.
By sector, the portfolio is most concentrated in Financials at 16% of assets, down from 17% a quarter earlier, followed by Technology and Healthcare.
On the sell side, the largest reduction was Biogen, an estimated $8.21M trimmed.
- RhumbLine Advisers's largest Q1 2017 buy was Bioverativ Inc. Common Stock: 197,812 shares worth $10.8M.
- RhumbLine Advisers added most to Abbott in Q1 2017, an estimated $21.8M increase.
- RhumbLine Advisers's biggest Q1 2017 reduction was Biogen, cutting an estimated $8.21M.
- RhumbLine Advisers fully exited Spectra Energy Corp Wi in Q1 2017, selling an estimated $49.6M.
- RhumbLine Advisers's ten largest holdings make up 15% of its $42.8B portfolio in Q1 2017.
- RhumbLine Advisers opened 39 new positions and closed 44 in Q1 2017.
- RhumbLine Advisers's portfolio value rose 8.5% quarter-over-quarter to $42.8B.
Based on RhumbLine Advisers's 13F filing for Q1 2017, filed 2 May 2017.